Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JESSICA BAUMAN

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1619139235
CMS profile
579955
Location
PHILADELPHIA, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$2,520.00

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Honoraria $2,520.00 1

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
PFIZER INC. $2,520.00 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JESSICA BAUMAN

NPI 1619139235 · CMS profile ID 579955

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

PHILADELPHIA, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1619139235?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JESSICA BAUMAN, NPI 1619139235, CMS profile ID 579955. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1619139235?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). JESSICA BAUMAN, NPI 1619139235, CMS profile ID 579955. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1619139235?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
JESSICA BAUMAN, NPI 1619139235, CMS profile ID 579955, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1619139235?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $2,520.00 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $2,520.0006/10/2022 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949352739 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $10,346.90 6
PY2021 $6,402.50 6
PY2022 $2,520.00 1
PY2023 $13,235.53 5
PY2024 $3,945.00 3
PY2025 $4,182.50 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $662,530.20 43
PY2024 Recipient $4,600.00 2
PY2024 Principal investigator $597,434.60 56
PY2023 Recipient $3,200.00 1
PY2023 Principal investigator $615,260.38 77
PY2022 Principal investigator $513,473.56 47
PY2021 Principal investigator $536,056.62 88
PY2020 Recipient $3,200.00 1
PY2020 Principal investigator $550,482.65 74
PY2019 Principal investigator $501,598.41 22

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

88 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $6,131.45 12/31/2021 Non-covered Recipient Entity
THE INSTITUTE FOR CANCER RESEARCH
A Phase II, Single Arm Study Assessing the Efficacy of Osimertinib in Combination with Savolitinib in Patients with EGFRm+ and MET+, Locally Advanced or Metastatic Non-Small Cell Lung Cancer who have Progressed Following Treatment with Osimertinib No dispute reported 06/30/2026 826502373
Principal investigator 1 Merck Sharp & Dohme Corporation $1,147.48 12/31/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A Phase III Randomized Trial of MK-3475 Versus Standard Treatment in Subjects with recurrent or metastatic head and neck cancer No dispute reported 06/30/2026 848742799
Principal investigator 1 Merck Sharp & Dohme Corporation $14,141.54 12/31/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma R,M cSCC No dispute reported 06/30/2026 848746449
Principal investigator 1 Merck Sharp & Dohme Corporation $6,599.59 12/31/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial No dispute reported 06/30/2026 848746581
Principal investigator 1 Merck Sharp & Dohme Corporation $30,305.08 12/31/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 No dispute reported 06/30/2026 848756405
Principal investigator 1 Merck Sharp & Dohme Corporation $43,369.54 12/31/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 No dispute reported 06/30/2026 848756407
Principal investigator 1 PFIZER INC. $10,305.07 12/22/2021 Covered Recipient Teaching Hospital
American Oncologic Hospial
PHASE 12 STUDY OF PF06463922 AN ALKROS1 TYROSINE KINASE INHIBITOR IN PATIENTS WITH ADVANCED NONSMALL CELL LUNG CANCER HARBORING SPECIFIC MOLECULAR ALTERATIONS No dispute reported 06/30/2026 832578073
Principal investigator 1 GlaxoSmithKline, LLC. $60,629.45 12/17/2021 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 No dispute reported 06/30/2026 860870527
Principal investigator 1 Merck Sharp & Dohme Corporation $7,391.00 12/17/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial No dispute reported 06/30/2026 848746579
Principal investigator 1 Merck Sharp & Dohme Corporation $30,116.06 12/15/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 No dispute reported 06/30/2026 848756403
Principal investigator 1 GlaxoSmithKline, LLC. $4,877.60 12/14/2021 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 No dispute reported 06/30/2026 860868787
Principal investigator 1 GlaxoSmithKline, LLC. $4,877.60 12/14/2021 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 No dispute reported 06/30/2026 860871093
Principal investigator 1 GlaxoSmithKline, LLC. $758.44 12/14/2021 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 No dispute reported 06/30/2026 860871095
Principal investigator 1 GlaxoSmithKline, LLC. $4,207.60 12/14/2021 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 No dispute reported 06/30/2026 860871097
Principal investigator 1 GlaxoSmithKline, LLC. $1,005.00 12/14/2021 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 No dispute reported 06/30/2026 860872257
Principal investigator 1 GlaxoSmithKline, LLC. $6,731.89 12/07/2021 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 No dispute reported 06/30/2026 860870513
Principal investigator 1 GlaxoSmithKline, LLC. $758.44 11/16/2021 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 No dispute reported 06/30/2026 809491937
Principal investigator 1 GlaxoSmithKline, LLC. $4,877.60 11/16/2021 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 No dispute reported 06/30/2026 809494989
Principal investigator 1 GlaxoSmithKline, LLC. $1,005.00 11/16/2021 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 No dispute reported 06/30/2026 809514161
Principal investigator 1 GlaxoSmithKline, LLC. $4,207.60 11/16/2021 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 No dispute reported 06/30/2026 809535223
Principal investigator 1 GlaxoSmithKline, LLC. $4,877.60 11/16/2021 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 No dispute reported 06/30/2026 809535271
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,340.00 10/27/2021 Non-covered Recipient Entity
Institute For Cancer Research Dba Research Institute Of Fox Chase Cancer Center
A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy No dispute reported 06/30/2026 819895331
Principal investigator 1 GlaxoSmithKline, LLC. $758.44 10/15/2021 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 No dispute reported 06/30/2026 809487597
Principal investigator 1 GlaxoSmithKline, LLC. $4,207.60 10/15/2021 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 No dispute reported 06/30/2026 809487625
Principal investigator 1 GlaxoSmithKline, LLC. $4,877.60 10/15/2021 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 No dispute reported 06/30/2026 809488017
Principal investigator 1 GlaxoSmithKline, LLC. $1,005.00 10/15/2021 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 No dispute reported 06/30/2026 809488043
Principal investigator 1 GlaxoSmithKline, LLC. $4,877.60 10/15/2021 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 No dispute reported 06/30/2026 809488045
Principal investigator 1 BeiGene, Ltd. $500.00 09/27/2021 Non-covered Recipient Entity
Fox Chase Cancer Center
Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 855854801
Principal investigator 1 BeiGene, Ltd. $2,400.00 09/27/2021 Non-covered Recipient Entity
Fox Chase Cancer Center
Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 855854803
Principal investigator 1 BeiGene, Ltd. $4,530.00 09/27/2021 Non-covered Recipient Entity
Fox Chase Cancer Center
Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 855854805
Principal investigator 1 BeiGene, Ltd. $1,000.00 09/27/2021 Non-covered Recipient Entity
Fox Chase Cancer Center
Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 855854807
Principal investigator 1 BeiGene, Ltd. $1,030.00 09/27/2021 Non-covered Recipient Entity
Fox Chase Cancer Center
Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 855854809
Principal investigator 1 PFIZER INC. $1,000.00 09/22/2021 Non-covered Recipient Entity
Institute for Cancer Research
A PHASE 1B 12WEEK OPENLABEL STUDY TO ASSESS THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS FOLLOWING REPEATED SUBCUTANEOUS ADMINISTRATIONS OF PF06946860 IN PATIENTS WITH CANCER AND CACHEXIA No dispute reported 06/30/2026 832803169
Principal investigator 1 BeiGene, Ltd. $342.00 09/20/2021 Non-covered Recipient Entity
Fox Chase Cancer Center
Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 855854829
Principal investigator 1 GlaxoSmithKline, LLC. $2,000.00 09/16/2021 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 No dispute reported 06/30/2026 809490275
Principal investigator 1 BeiGene, Ltd. $6,534.00 09/01/2021 Non-covered Recipient Entity
Fox Chase Cancer Center
Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 855854811
Principal investigator 1 BeiGene, Ltd. $5,226.00 09/01/2021 Non-covered Recipient Entity
Fox Chase Cancer Center
Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 855854813
Principal investigator 1 BeiGene, Ltd. $8,777.00 09/01/2021 Non-covered Recipient Entity
Fox Chase Cancer Center
Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 855854815
Principal investigator 1 BeiGene, Ltd. $713.00 09/01/2021 Non-covered Recipient Entity
Fox Chase Cancer Center
Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 855854817
Principal investigator 1 BeiGene, Ltd. $293.00 09/01/2021 Non-covered Recipient Entity
Fox Chase Cancer Center
Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 855854819
Principal investigator 1 BeiGene, Ltd. $168.00 09/01/2021 Non-covered Recipient Entity
Fox Chase Cancer Center
Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 855854821
Principal investigator 1 BeiGene, Ltd. $162.00 09/01/2021 Non-covered Recipient Entity
Fox Chase Cancer Center
Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 855854823
Principal investigator 1 BeiGene, Ltd. $258.00 09/01/2021 Non-covered Recipient Entity
Fox Chase Cancer Center
Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 855854825
Principal investigator 1 BeiGene, Ltd. $197.00 09/01/2021 Non-covered Recipient Entity
Fox Chase Cancer Center
Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 855854827
Principal investigator 1 PFIZER INC. $35,683.49 07/21/2021 Covered Recipient Teaching Hospital
American Oncologic Hospial
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF AVELUMAB IN COMBINATION WITH STANDARD OF CARE CHEMORADIOTHERAPY CISPLATIN PLUS DEFINITIVE RADIATION THERAPY VERSUS STANDARD OF CARE CHEMORADIOTHERAPY IN THE FRONTLINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK No dispute reported 06/30/2026 832871971
Principal investigator 1 PFIZER INC. $18,520.00 06/22/2021 Non-covered Recipient Entity
Institute for Cancer Research
A PHASE 1B 12WEEK OPENLABEL STUDY TO ASSESS THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS FOLLOWING REPEATED SUBCUTANEOUS ADMINISTRATIONS OF PF06946860 IN PATIENTS WITH CANCER AND CACHEXIA No dispute reported 06/30/2026 832692767
Principal investigator 1 GlaxoSmithKline, LLC. $3,417.00 06/17/2021 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 No dispute reported 06/30/2026 809481441
Principal investigator 1 GlaxoSmithKline, LLC. $1,507.50 06/17/2021 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 No dispute reported 06/30/2026 809481443
Principal investigator 1 GlaxoSmithKline, LLC. $7,316.40 06/17/2021 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 No dispute reported 06/30/2026 809481445
Principal investigator 1 GlaxoSmithKline, LLC. $6,311.40 06/17/2021 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 No dispute reported 06/30/2026 809481741
Principal investigator 1 GlaxoSmithKline, LLC. $4,877.60 06/17/2021 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 No dispute reported 06/30/2026 809481767
Principal investigator 1 GlaxoSmithKline, LLC. $758.44 06/17/2021 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 No dispute reported 06/30/2026 809481769
Principal investigator 1 GlaxoSmithKline, LLC. $1,768.80 06/17/2021 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 No dispute reported 06/30/2026 809490345
Principal investigator 1 GlaxoSmithKline, LLC. $268.00 06/17/2021 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 No dispute reported 06/30/2026 809490395
Principal investigator 1 PFIZER INC. $236.17 05/21/2021 Covered Recipient Teaching Hospital
American Oncologic Hospial
A 6WEEK RANDOMIZED DOUBLEBLIND SPONSOROPEN STUDY TO ASSESS THE EFFECT OF REPEATED SUBCUTANEOUS ADMINISTRATION OF PF06946860 ON APPETITE IN PARTICIPANTS WITH ADVANCED CANCER AND ANOREXIA FOLLOWED BY AN 18WEEK OPENLABEL TREATMENT PERIOD No dispute reported 06/30/2026 948971421
Principal investigator 1 BeiGene, Ltd. $1,829.00 05/04/2021 Non-covered Recipient Entity
Fox Chase Cancer Center
Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 855854775
Principal investigator 1 BeiGene, Ltd. $1,494.00 05/04/2021 Non-covered Recipient Entity
Fox Chase Cancer Center
Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 855854777
Principal investigator 1 BeiGene, Ltd. $1,688.00 05/04/2021 Non-covered Recipient Entity
Fox Chase Cancer Center
Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 855854791
Principal investigator 1 BeiGene, Ltd. $1,494.00 05/04/2021 Non-covered Recipient Entity
Fox Chase Cancer Center
Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 855854797
Principal investigator 1 Amgen Inc. $7,901.00 04/24/2021 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
AMG 510 Expanded access ex EU (w/LTFU) No dispute reported 06/30/2026 830979041
Principal investigator 1 BeiGene, Ltd. $44.00 04/21/2021 Non-covered Recipient Entity
Fox Chase Cancer Center
Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 855854767
Principal investigator 1 BeiGene, Ltd. $5,226.00 04/21/2021 Non-covered Recipient Entity
Fox Chase Cancer Center
Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 855854769
Principal investigator 1 BeiGene, Ltd. $197.00 04/21/2021 Non-covered Recipient Entity
Fox Chase Cancer Center
Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 855854771
Principal investigator 1 BeiGene, Ltd. $162.00 04/21/2021 Non-covered Recipient Entity
Fox Chase Cancer Center
Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 855854779
Principal investigator 1 BeiGene, Ltd. $147.00 04/21/2021 Non-covered Recipient Entity
Fox Chase Cancer Center
Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 855854781
Principal investigator 1 BeiGene, Ltd. $154.00 04/21/2021 Non-covered Recipient Entity
Fox Chase Cancer Center
Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 855854783
Principal investigator 1 BeiGene, Ltd. $713.00 04/21/2021 Non-covered Recipient Entity
Fox Chase Cancer Center
Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 855854785
Principal investigator 1 BeiGene, Ltd. $293.00 04/21/2021 Non-covered Recipient Entity
Fox Chase Cancer Center
Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 855854789
Principal investigator 1 BeiGene, Ltd. $168.00 04/21/2021 Non-covered Recipient Entity
Fox Chase Cancer Center
Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 855854793
Principal investigator 1 BeiGene, Ltd. $293.00 04/21/2021 Non-covered Recipient Entity
Fox Chase Cancer Center
Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 855854795
Principal investigator 1 BeiGene, Ltd. $258.00 04/21/2021 Non-covered Recipient Entity
Fox Chase Cancer Center
Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 855854799
Principal investigator 1 BeiGene, Ltd. $1,944.00 04/09/2021 Non-covered Recipient Entity
Fox Chase Cancer Center
Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 855854787
Principal investigator 1 PFIZER INC. $18,291.00 04/08/2021 Covered Recipient Teaching Hospital
American Oncologic Hospial
PHASE 12 STUDY OF PF06463922 AN ALKROS1 TYROSINE KINASE INHIBITOR IN PATIENTS WITH ADVANCED NONSMALL CELL LUNG CANCER HARBORING SPECIFIC MOLECULAR ALTERATIONS No dispute reported 06/30/2026 832872483
Principal investigator 1 BeiGene, Ltd. $3,221.00 04/05/2021 Non-covered Recipient Entity
Fox Chase Cancer Center
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Clinical Study Comparing the Efficacy and Safety of Tislelizumab (BGB-A317) Plus Platinum and Fluoropyrimidine Versus Placebo Plus Platinum and Fluoropyrimidine as First-Line Treatment in Patients Wi No dispute reported 06/30/2026 855854765
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $4,107.40 04/01/2021 Non-covered Recipient Entity
Fox Chase Cancer Center
A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy No dispute reported 06/30/2026 819894187
Principal investigator 1 GlaxoSmithKline, LLC. $4,207.60 03/24/2021 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 No dispute reported 06/30/2026 809479837
Principal investigator 1 GlaxoSmithKline, LLC. $379.22 03/24/2021 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 No dispute reported 06/30/2026 809480005
Principal investigator 1 GlaxoSmithKline, LLC. $3,417.00 03/24/2021 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 No dispute reported 06/30/2026 809480075
Principal investigator 1 GlaxoSmithKline, LLC. $4,877.60 03/24/2021 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 No dispute reported 06/30/2026 809480255
Principal investigator 1 GlaxoSmithKline, LLC. $1,005.00 03/24/2021 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 No dispute reported 06/30/2026 809480257
Principal investigator 1 GlaxoSmithKline, LLC. $268.00 03/24/2021 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 No dispute reported 06/30/2026 809483151
Principal investigator 1 GlaxoSmithKline, LLC. $2,438.80 03/24/2021 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 No dispute reported 06/30/2026 809487265
Principal investigator 1 Amgen Inc. $4,930.96 03/11/2021 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
AMG 510 Expanded access ex EU (w/LTFU) No dispute reported 06/30/2026 830979043
Principal investigator 1 AstraZeneca Pharmaceuticals LP $43,091.15 03/10/2021 Non-covered Recipient Entity
THE INSTITUTE FOR CANCER RESEARCH
A Phase II, Single Arm Study Assessing the Efficacy of Osimertinib in Combination with Savolitinib in Patients with EGFRm+ and MET+, Locally Advanced or Metastatic Non-Small Cell Lung Cancer who have Progressed Following Treatment with Osimertinib No dispute reported 06/30/2026 826478319
Principal investigator 1 GlaxoSmithKline, LLC. $1,000.00 03/10/2021 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 No dispute reported 06/30/2026 809480077
Principal investigator 1 PFIZER INC. $1,250.00 03/10/2021 Covered Recipient Teaching Hospital
American Oncologic Hospial
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF AVELUMAB IN COMBINATION WITH STANDARD OF CARE CHEMORADIOTHERAPY CISPLATIN PLUS DEFINITIVE RADIATION THERAPY VERSUS STANDARD OF CARE CHEMORADIOTHERAPY IN THE FRONTLINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK No dispute reported 06/30/2026 832772541
Principal investigator 1 GlaxoSmithKline, LLC. $21,385.22 02/26/2021 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 No dispute reported 06/30/2026 809478245
Principal investigator 1 PFIZER INC. $17,000.00 02/05/2021 Non-covered Recipient Entity
Institute for Cancer Research
A PHASE 1B 12WEEK OPENLABEL STUDY TO ASSESS THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS FOLLOWING REPEATED SUBCUTANEOUS ADMINISTRATIONS OF PF06946860 IN PATIENTS WITH CANCER AND CACHEXIA No dispute reported 06/30/2026 832857121